However, the more expensive the drug, the fewer people can afford it
[19] During the initial titration phase for subcutaneous semaglutide (Ozempic), the starting dose of 0.25 mg once weekly for the first 4 weeks is primarily for acclimation to minimize gastrointestinal side effects, with very little to no significant weight loss expected (typically 03 pounds or ~02% of body weight, mainly from reduced appetite and possible water weight)
Are ready to commit to a long-term weight loss journey, including the necessary lifestyle changes that support the medication
Major weight loss affects the whole body, including the face, and can definitely impact volume in the jowls and cheeks, among other places. This is what Deneuve meant when she said one had to choose: when we lose a lot of volume in the body, our face can follow suit, aging our appearance
Download our latest whitepaper to discover a comprehensive analysis of current trends, regulatory dynamics, alternative access pathways, and the evolving global trial environment for GLP-1 receptor agonists: To view or add a comment, sign in The evolution of GLP-1 therapies is creating one of the most dynamic areas in drug development today
